

Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Med J 2012;53:931-9.

Minkyu Jung,^{1,2} Se Hyun Kim,^{1,2} Soojung Hong,^{1,2} Young Ae Kang,³ Se Kyu Kim,³ Joon Chang,³
Sun Young Rha,^{1,2} Joo Hang Kim,^{1,2} Dae Joon Kim,⁴ and Byoung Chul Cho^{1,2}

¹Yonsei Cancer Center, ²Division of Medical Oncology, ³Division of Pulmonology, Department of Internal Medicine, and

⁴Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.

Dear Editor

We deeply regret to inform you that our paper was submitted twice to two different Journals, and was already published in another Journal¹; therefore, we are requesting to retract our paper that has been published in YMJ.² We mistakenly submitted our paper to the other journal. As the corresponding author, I will take full responsibility for this error and respectfully request for the retraction of our paper from YMJ.

1. Jung M, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, et al. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. *Exp Ther Med* 2011;2:685-93.
2. Jung M, Kim SH, Hong S, Kang YA, Kim SK, Chang J, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. *Yonsei Med J* 2012;53:931-9.